Skip to main content

Everything we do at Amylyx is centered around those living with neurodegenerative diseases. We are on a mission to discover and develop treatments for relentless neurodegenerative diseases and to help support and create more moments for the neurodegenerative community.

FDA Approves RELYVRIO™ (previously known as AMX0035) for the treatment of adults with ALS in the U.S.

Amylyx is proud to announce that the U.S. Food and Drug Administration (FDA) has approved RELYVRIO™ (sodium phenylbutyrate and taurursodiol [also known as ursodoxicoltaurine]), for the treatment of adults with amyotrophic lateral sclerosis (ALS) in the U.S.

Health Canada Approves ALBRIOZA™ (sodium phenylbutyrate and ursodoxicoltaurine) for the Treatment of ALS

Amylyx is proud to announce that Health Canada has approved ALBRIOZA (sodium phenylbutyrate and ursodoxicoltaurine), with conditions, for the treatment of amyotrophic lateral sclerosis (ALS). ALBRIOZA (previously known as AMX0035) is an oral fixed-dose combination therapy that may reduce neuronal cell death in people living with ALS, either as a stand-alone therapy or when added to existing treatments.

In pursuit of more

Our ongoing commitment to discovery carries with it a responsibility to be transparent, set realistic expectations, and work together to make an impact. Learn more about our unique culture, approach to clinical trials and more.

Our ongoing commitment to discovery carries with it a responsibility to be transparent, set realistic expectations, and work together to make an impact. Learn more about our unique culture, approach to clinical trials and more.

Latest News